LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Corcept Therapeutics Inc

Chiusa

SettoreSettore sanitario

69.62 1.1

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

68.58

Massimo

70.41

Metriche Chiave

By Trading Economics

Entrata

-9.8M

21M

Vendite

-25M

157M

P/E

Media del settore

62.33

51.198

EPS

0.169

Margine di Profitto

13.069

Dipendenti

500

EBITDA

-22M

3.4M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+101.9% upside

Dividendi

By Dow Jones

Utili prossimi

28 lug 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-111M

7.6B

Apertura precedente

68.52

Chiusura precedente

69.62

Notizie sul Sentiment di mercato

By Acuity

44%

56%

151 / 380 Classifica in Healthcare

Corcept Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

6 giu 2025, 14:31 UTC

Utili

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 20:33 UTC

Utili

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 19:36 UTC

Discorsi di Mercato

Oil Futures Post Solid Weekly Gains -- Market Talk

6 giu 2025, 19:28 UTC

Discorsi di Mercato

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 giu 2025, 18:46 UTC

Discorsi di Mercato

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 giu 2025, 18:02 UTC

Discorsi di Mercato

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 giu 2025, 16:35 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:34 UTC

Utili

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 giu 2025, 16:21 UTC

Discorsi di Mercato

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

6 giu 2025, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

6 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

6 giu 2025, 16:07 UTC

Discorsi di Mercato

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 giu 2025, 15:53 UTC

Discorsi di Mercato

Mexican Inflation Seen Rising in May -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 giu 2025, 15:36 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 15:33 UTC

Discorsi di Mercato

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 giu 2025, 15:16 UTC

Discorsi di Mercato

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 giu 2025, 15:05 UTC

Discorsi di Mercato

Silver at its Highest In Nearly 15 Years -- Market Talk

6 giu 2025, 14:35 UTC

Discorsi di Mercato

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

6 giu 2025, 14:28 UTC

Discorsi di Mercato

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 giu 2025, 14:15 UTC

Discorsi di Mercato

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 giu 2025, 14:12 UTC

Utili

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 giu 2025, 14:09 UTC

Utili

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Confronto tra pari

Modifica del prezzo

Corcept Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

101.9% in crescita

Previsioni per 12 mesi

Media 139.33 USD  101.9%

Alto 145 USD

Basso 131 USD

Basato su 4 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Corcept Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

4 ratings

4

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

151 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Corcept Therapeutics Inc

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.